CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Highlights Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - NYSE 06:00:03 23/09/26 am AEST			5-day change	1st Jan Change
285.11 ^USD	+2.19%		+4.48%	+42.93%

17/09	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
17/09	Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating	MT

Highlights

17/09	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
17/09	Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says	MT
08/09	Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite	CI
20/08	Charles River, Medigen Partner on Multivalent Enterovirus Vaccine	MT
06/08	Top Midday Gainers	MT
05/08	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
05/08	Charles River Laboratories International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 27, 2026	CI
05/08	Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Fall; Lifts 2026 Guidance	MT
05/08	Charles River Laboratories International, Inc. Updates Earnings Guidance for 2026	CI
05/08	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11	MT
05/08	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M	MT
05/08	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Adjusted EPS $3.02, vs. FactSet Est of $2.74	MT
05/08	Charles River lifts profit forecast on improving biotech demand	RE
14/07	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
13/07	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI
13/05	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing	MT
12/05	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors	CI
12/05	Charles River Laboratories International, Inc. Accelerates Digital Pathology with Ai-Powered End-To-End Workflow	CI
08/05	Charles River Laboratories International, Inc. Seeks M&A Opportunities	CI
08/05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
07/05	Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026	CI
07/05	Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance	MT
07/05	(CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08	MT
07/05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q1 Adjusted EPS $2.06 per Share, vs. FactSet Est of $1.94	MT
07/05	Charles River beats quarterly estimates on steady demand for drug development services	RE